ProQR Therapeutics N.V.

NASDAQ:PRQR

Biotechnology

Healthcare
$1.10 +12.28%

+$0.21 today

Market cap
$155.23M
Beta
0.06
P/E (TTM)
-3.8
EPS (TTM)
-$0.43
52W Low $1.33High $3.10

Volume 0.88M

Average 0.62M

PRQR Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

ProQR Therapeutics N.V.NASDAQ: PRQR

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures dips below year-ago levels

Q1 FY2026 capital expenditures of €166.7K (cash outflow) fell 25.6% year over year, behind the +5.0% change in trailing-twelve-month capital expenditures. Sequentially, it fell 67.9% from the prior quarter. Over 3 fiscal years it compounded at +11.4% a year.

Context

  • Capital expenditures amounted to 6.4% of revenue in FY2025, down 1.1 pp from a year earlier.
  • Capital expenditures grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -25.6% toward the trailing-twelve-month pace of +5.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-€166.7K-67.9% QoQ
Last fiscal yearDec 2025
-€979.75K-30.9% YoY
LTMMar 2026
-€955.79K+5.0% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-25.6%——
1 year-30.9%——
3-year CAGR+11.4%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

EUR · from the cash flow

Latest · FY2025
(979.75K) EUR
Year-over-year change
+30.9%

Capital Expenditures vs competitors

How PRQR compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +5.0% is the 3rd highest of 10, against a peer median of -41.5%.
  • Capital expenditures amounts to 7.1% of revenue for PRQR, versus a peer median of 0.8%.
PRQR Competitors
Capital Expenditures for PRQR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$21.33M USD+958.6%-4.7%—
PRQRProQR Therapeutics N.V.LTM Mar 2026€955.79K EUR+5.0%+11.4%7.1%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$783K USD-14.8%+13.7%0.4%
EDITEditas Medicine, Inc.LTM Mar 2026$585K USD-91.7%-47.2%1.5%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$318.66K USD-41.5%-69.0%0.7%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$296K USD-62.3%-57.9%—
ZURAZura Bio LimitedLTM Mar 2026$77K USD-34.2%-78.9%—
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$59K USD+101.7%-28.8%1.0%
IMMPImmutep LimitedFY2025A$45.77K AUD-95.1%+25.9%0.9%
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$3K USD———
MREOMereo BioPharma Group plcLTM Mar 2026$1.52K USD-99.5%+15.4%0.3%
Peer median (excluding PRQR) —-41.5%-28.8%0.8%

Competitors are the stored peer set for PRQR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(60.8M)(64.2M)(27.74M)(27.76M)(40.52M)
Depreciation & Amortization2.33M2.52M2.51M2.76M2.6M
Deferred Income Tax117K96K(78K)(197K)0
Stock-Based Compensation6.22M2.87M3.11M2.54M0
Change in Working Capital25.01M(4.99M)48.96M(13.26M)(16.73M)
Accounts Receivables00000
Inventory00000
Accounts Payables00000
Other Working Capital25.01M(4.99M)48.96M(13.26M)(16.73M)
Other Non-Cash Items1.11M(4.8M)(5.21M)(474K)3.94M
Operating Cash Flow(26.01M)(68.51M)21.55M(36.39M)(50.71M)
Capital Expenditures(484K)(708K)(1.37M)(1.42M)(979.75K)
Acquisitions (Net)00000
Purchases of Investments000(17M)0
Sales of Investments00017M0
Other Investing Activities59K6K5.65M(2.66M)0
Investing Cash Flow(425K)(702K)4.28M(4.07M)(979.74K)
Debt Repayment26.84M(45.05M)(2.63M)(1.58M)(1.91M)
Common Stock Issued108.48M14.12M071.64M66.28K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.52M34K354K223K75.19K
Financing Cash Flow136.83M(30.89M)(2.28M)70.28M(1.76M)
Effect of Forex Changes1.29M7.35M599K673K14.15M
Net Change in Cash111.69M(92.75M)24.15M30.48M(39.3M)
Free Cash Flow(26.5M)(69.22M)20.18M(37.81M)(51.69M)

ProQR Therapeutics N.V.

NASDAQ:PRQR

Intrinsic Alpha fair value

Locked

Current Price

$1.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.